Ranbaxy Laboratories has ventured into planned in-licensing pact for the domestic market with Medy-Tox Inc (Medy-Tox), South Korea’s biggest Botulinum-Toxin expert Biotech Venture for its cosmetic produce, Neuronox.

The NSE Nifty cracked a 6 day upswing and hit lower due to feeble Asian cues.

The BSE Sensex traded up along with some instability while the NSE Nifty floated nearly the 4800 level at 10:47 hours IST.

Ranbaxy Pharmaceuticals Inc declared a deal with Validus Pharmaceuticals LLC to advertise and allocate a certified general edition of Rocaltrol(R) (calcitriol) in both soft gel tablets and an oral liquid formulation.

Ranbaxy Laboratories has declared that Terapia S.A. will promote the osteoporosis medication, Evista in Romania.

The company declared during trade hours on Monday, when the stock earned 3.05%.

Ranbaxy Laboratories presently trades at Rs.321.95, which is 10.50 points high from its earlier closing of Rs.311.45 on the Sensex.

Reportedly, Ranbaxy Laboratories has announced that it bagged consent from the USFDA to produce and market Glycopyrrolate medicine USP, 1 mg and 2 mg.

The BSE Sensex continued to dip and was heading towards the 15,000 level at 11:48 hours IST.

Market had a range bound session today.